Matthias Guckenberger, Professor and Chairman of Department of Radiation Oncology at USZ and UZH, shared a post on LinkedIn:
” Oligometastatic cancer patient treated with stereotactic radiotherapy for two metastases.
- Patient cancer-free and systemic therapy-free for several years.
- One new metastasis, amendable for safe metastasis-directed therapy.
- Success.
- Failure.
- Continue ‘local’ treatment strategy.
- Change of treatment strategy.
Subproject of E2R OligoCare Consortium:
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium
- Polymetastatic progression-free survival.
- Start-or-switch of systemic therapy-free survival.
- Time-to-deterioration of quality of life.”
Title: Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium
Authors: Joachim Widder, Guus M Bol, Inga-Malin Simek, Felix Ehret, Hoda Abdel-Aty, Selma Basic, David Chuter, Jacqueline Daly, Patricia Fairbrother, Donjeta Zeqa, Frank Aboubakar Nana, Verane Achard, Stefanie Corradini, Dora Correia, Dirk De Ruysscher, Anne-Marie C Dingemans, Corinne Faivre-Finn, Silke Gillessen, Marianne G Guren, Lizza Hendriks, Wolfgang G Kunz, Frederic E Lecouvet, Antonin Levy, Yolande Lievens, Fiona McDonald, Icro Meattini, Felix Oppong, Daniela Oprea-Lager, David Palma, Gitte Fredberg Persson, Jordi Remon, Miet Vandemaele, Hanneke W M van Laarhoven, Helena M Verkooijen, Luca Visani, Thomas Zilli, Piet Ost, Matthias Guckenberger
Read the full article on Science Direct
Other articles featuring Matthias Guckenberger on OncoDaily.